Abstract
Post-translational ubiquitination is an essential mechanism for the regulation of protein stability and function, which contributes to the regulation of the immune system. Cbl, an E3 ubiquitin ligase, is particularly well-characterized in the context of T and NK cell signaling, where it serves as a key regulator of receptor downstream signaling events and as a modulator of cell activation. Cbl promotes the proteasomal degradation of TCR/CD3 subunits as well as the protein kinases Fyn and Lck in T cells. Additionally, the scaffold protein linker for activation of T cells (LAT) is a universal target for Cbl-mediated ubiquitination and degradation in both T and NK cells. Recent findings suggest that CrkII-mediated ubiquitination and degradation of C3G by Cbl during early T cell activation may also be relevant to NK cell signaling. Given its role in modulating immune responses and its manageable impact on autoimmunity, Cbl is being investigated as a target for cancer immunotherapy. This review explores the ubiquitin ligase activity of Cbl and its implications for CAR T and NK cell immunotherapies.
Original language | English |
---|---|
Article number | 1592 |
Journal | Life |
Volume | 14 |
Issue number | 12 |
DOIs | |
State | Published - 1 Dec 2024 |
Keywords
- C3G
- cancer immunotherapy
- CAR-T cells
- Cbl
- LAT
- NK cell
- proteasomal degradation
- signal transduction
- T cell
- TCR
- ubiquitin
ASJC Scopus subject areas
- Ecology, Evolution, Behavior and Systematics
- General Biochemistry, Genetics and Molecular Biology
- Space and Planetary Science
- Paleontology